Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

Wirralboy Oct. 25 at 3:07 PM

$CABA Analyst consensus for Cabaletta Bio (CABA) has an average price target around $12.25 to $13.44, with a high estimate of up to $22 or even higher and a low estimate around $2.00 to $3.00. The consensus rating among analysts is generally "Buy" or "Strong Buy". Analyst consensus Average Price Target: Approximately $12.25 to $13.44 High Price Target: Up to $22.00 or $25.00 Low Price Target: Around $2.00 to $3.00 Consensus Rating: "Buy" or "Strong Buy"

1 · Reply

vessp312 Oct. 24 at 11:19 PM

$CABA My mother passed away from scleroderma couple of years ago. I remember seeing at the time that there was no meds, treatments but only some upcoming trials. I'm usually not investing in pharma but I stumbled upon this company and I saw that one of their goals is developing a treatment for scleroderma. All I can is I'm in and even if it might be too late for my mother, I'm really hoping that they will succeed in stopping this terrible disease

2 · Reply

steven134 Oct. 24 at 10:19 PM

$CABA where is the announcement?

1 · Reply

Majlo Oct. 24 at 10:01 PM

$CABA aftermarket does not look promising 😅

0 · Reply

jerzypawlik Oct. 24 at 8:20 PM

$CABA This is just beginning of a beautiful journey. Anything below this price is a bargain.

0 · Reply

steven134 Oct. 24 at 7:10 PM

$CABA where is the trial data?

1 · Reply

Moonman321 Oct. 24 at 6:17 PM

$CABA $FVRR $NVDA $QBTS $SKIN I’m going to Small cap heaven !!!

0 · Reply

Moonman321 Oct. 24 at 6:15 PM

$CABA $QBTS $NVDA $SKIN $FVRR how can you be a 🐻 at this stage of the game? Because they have no money to go Long !!they buy cheap puts 😆 what a bunch of numb nuts These parasites will be paying me for a long time to come Don’t say those famous words I wish I would’ve bought more Caba

0 · Reply

Bronco6970 Oct. 24 at 5:35 PM

$CABA loaded with 20k, leaving some in the reserve if we retrace. Will buy all dips from here if necessary. Let’s go! 🚀🔥👊🏻

0 · Reply

Bronco6970 Oct. 24 at 5:33 PM

$CABA big sell wall just got knocked out 🚀

0 · Reply

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Oct 9, 2025, 12:00 PM EDT - 16 days ago

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Oct 7, 2025, 6:20 AM EDT - 18 days ago

Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon

Aug 27, 2025, 8:00 AM EDT - 2 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 7, 2025, 7:30 AM EDT - 2 months ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 11:07 AM EDT - 3 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT NGNE NTLA QURE RCKT

Jun 11, 2025, 9:54 AM EDT - 4 months ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:49 AM EDT - 4 months ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 6:15 AM EDT - 4 months ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 4 months ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

May 29, 2025, 8:00 AM EDT - 5 months ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 5 months ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Mar 31, 2025, 7:00 AM EDT - 7 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 7:00 AM EDT - 7 months ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Feb 26, 2025, 8:00 AM EST - 8 months ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 8 months ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 8 months ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 9 months ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Jan 29, 2025, 8:00 AM EST - 9 months ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 6, 2025, 2:28 PM EST - 10 months ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 1 year ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 1 year ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 1 year ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 2 years ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 2 years ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 2 years ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 2 years ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 2 years ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 19, 2023, 4:56 AM EDT - 2 years ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

May 31, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 22, 2023, 4:30 PM EDT - 2 years ago

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 21, 2023, 8:20 AM EDT - 2 years ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CYH EXAS MRNA NVAX ORGO PFE RARE

May 17, 2023, 10:16 PM EDT - 2 years ago

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 17, 2023, 4:01 PM EDT - 2 years ago

Cabaletta Bio Announces Proposed Public Offering of Common Stock

Wirralboy Oct. 25 at 3:07 PM

1 · Reply

vessp312 Oct. 24 at 11:19 PM

2 · Reply

steven134 Oct. 24 at 10:19 PM

$CABA where is the announcement?

1 · Reply

Majlo Oct. 24 at 10:01 PM

$CABA aftermarket does not look promising 😅

0 · Reply

jerzypawlik Oct. 24 at 8:20 PM

$CABA This is just beginning of a beautiful journey. Anything below this price is a bargain.

0 · Reply

steven134 Oct. 24 at 7:10 PM

$CABA where is the trial data?

1 · Reply

Moonman321 Oct. 24 at 6:17 PM

$CABA $FVRR $NVDA $QBTS $SKIN I’m going to Small cap heaven !!!

0 · Reply

Moonman321 Oct. 24 at 6:15 PM

0 · Reply

Bronco6970 Oct. 24 at 5:35 PM

$CABA loaded with 20k, leaving some in the reserve if we retrace. Will buy all dips from here if necessary. Let’s go! 🚀🔥👊🏻

0 · Reply

Bronco6970 Oct. 24 at 5:33 PM

$CABA big sell wall just got knocked out 🚀

0 · Reply

nutkicker Oct. 24 at 5:14 PM

$CABA fuck it. CABA, please hit $40 by EOY for all my stupid pain and suffering. And maybe to get these annoying pump and dump accounts to quiet down. I just need to stop feeling so hopeless all the time

0 · Reply

dantes13 Oct. 24 at 5:08 PM

$CABA news coming and 10$🍸❓️🤔🔥🔥🔥🔥🔥🔥🔥🔥🕔🐌🐌

1 · Reply

Majlo Oct. 24 at 4:01 PM

$CABA oh fuck we are green, its unbelievable

1 · Reply

Bronco6970 Oct. 24 at 3:55 PM

$CABA it’s starting to bubble

0 · Reply

JaOverLebron Oct. 24 at 3:10 PM

$TMC $CABA Dumped This weeks paycheck into both lets go!!

0 · Reply

Majlo Oct. 24 at 2:32 PM

$CABA next support 2.3 sweet

0 · Reply

Bronco6970 Oct. 24 at 2:19 PM

$CABA 17k shares, still adding. 🚀

0 · Reply

JaOverLebron Oct. 24 at 1:57 PM

$CABA Avg is 2.6 , I’m down 8% but holding until 20

0 · Reply

nutkicker Oct. 24 at 1:49 PM

$CABA is a $3 floor that hard to ask for someday jesus fuck

0 · Reply

Moonman321 Oct. 24 at 1:31 PM

$CABA this baby is ready to explode

1 · Reply

Stockholm111 Oct. 24 at 1:15 PM

$CABA Buying pressure has been greater than selling pressure over the past 4 days despite being knocked down 40 cents

0 · Reply

Moonman321 Oct. 24 at 1:07 PM

$QBTS $CABA oh yeah Light CPI

0 · Reply

Market Cap	220.43M
Revenue (ttm)	0.00
Net Income (ttm)	-115.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,847,600
Avg Vol	3,123,736
Day's Range	N/A - N/A
Shares Out	91.47M
Stochastic %K	15%
Beta	3.01
Analysts	Strong Sell
Price Target	$11.55